NCT06540144Active, not recruitingPhase 3
An extension study to find out if multiple treatment cycles of rozanolixizumab are safe and work in children with myasthenia gravis
An open-label Extension study to evaluate rozanolixizumab in pediatric study participants with generalized myasthenia gravis
Source: EU CTIS (euclinicaltrials.eu) · Last updated 7 Sept 2026
Brief summary (registry, in English)
Assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 7 (estimated)
- First submitted
- 3 Oct 2023
- Start date
- 8 Oct 2024
- Lead sponsor
- UCB Biopharma
- Diseases
- Myasthenia gravis
- NCT number
- NCT06540144
- EU CT number
- 2022-502075-34-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 7
- 5 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Lab values
- Study participant met any mandatory withdrawal or mandatory permanent IMP discontinuation criteria in MG0006 or permanently discontinued IMP - Study participant has a known hypersensitivity to any components of the IMP or other FcRn drugs - Study participant has any laboratory abnormality that, in the opinion of the Investigator, is clinically significant, has not resolved at Baseline, and could jeopardize or compromise the study participant’s ability to participate in this study
Who the study is looking for
- Study participant must meet one of the following: - −Study participant completed MG0006 according to the protocol - −Study participant completed the MG0006 Treatment Period and has a worsening of gMG symptoms in the Observation Period of MG0006
Age in the registry: - to 64 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Azienda Unita Sanitaria Locale Di Bologna Coordinator of this site? Confirm its status | Bologna | Italy | Active, not recruiting |
| IRCCS Foundation Istituto Neurologico Carlo Besta Coordinator of this site? Confirm its status | Milan | Italy | Active, not recruiting |
| Azienda Ospedaliera Santobono Pausilipon Coordinator of this site? Confirm its status | Naples | Italy | Active, not recruiting |
| Amicare Sp. z o.o. S.K. Coordinator of this site? Confirm its status | Lodz | Poland | Active, not recruiting |
| Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Coordinator of this site? Confirm its status | Warsaw | Poland | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.